Faithward Advisors LLC Buys 9,065 Shares of Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Faithward Advisors LLC increased its stake in Jazz Pharmaceuticals by 31.0% in the first quarter, buying 9,065 shares and bringing its total holdings to 38,339 shares valued at about $7.7 million.
• Jazz Pharmaceuticals shares were up 1.9% to $230.25, near the stock’s 52-week high of $243.32, while the company reported quarterly EPS of $6.34 on revenue of $1.07 billion.
• Analyst sentiment remains positive, with several firms raising price targets; the stock currently carries a Moderate Buy consensus and an average target price of $246.06.

Faithward Advisors LLC boosted its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 31.0% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 38,339 shares of the specialty pharmaceutical company's stock after buying an additional 9,065 shares during the period. Jazz Pharmaceuticals accounts for approximately 1.0% of Faithward Advisors LLC's portfolio, making the stock its 25th largest position. Faithward Advisors LLC owned 0.06% of Jazz Pharmaceuticals worth $7,717,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of JAZZ. Hilltop National Bank bought a new stake in shares of Jazz Pharmaceuticals during the fourth quarter valued at approximately $36,000. LRI Investments LLC bought a new position in Jazz Pharmaceuticals in the fourth quarter worth $38,000. Danske Bank A S purchased a new position in Jazz Pharmaceuticals during the third quarter valued at $40,000. Geneos Wealth Management Inc. lifted its position in Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company's stock valued at $47,000 after buying an additional 137 shares during the period. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in shares of Jazz Pharmaceuticals by 1,383.3% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company's stock valued at $47,000 after buying an additional 332 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Trading Up 1.9%

NASDAQ:JAZZ opened at $230.25 on Wednesday. The stock has a market cap of $14.46 billion, a price-to-earnings ratio of -11,506.75, a PEG ratio of 0.20 and a beta of 0.32. The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. The company's 50 day moving average price is $222.61 and its 200-day moving average price is $191.53. Jazz Pharmaceuticals PLC has a 52 week low of $105.00 and a 52 week high of $243.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. The company had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. On average, equities research analysts forecast that Jazz Pharmaceuticals PLC will post 22.09 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on JAZZ shares. UBS Group raised shares of Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $188.00 to $307.00 in a research note on Tuesday, May 19th. Morgan Stanley reissued an "overweight" rating and issued a $245.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, May 7th. Royal Bank Of Canada raised their price objective on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an "outperform" rating in a research report on Wednesday, May 6th. Truist Financial set a $256.00 price objective on Jazz Pharmaceuticals and gave the company a "buy" rating in a research note on Tuesday, June 9th. Finally, Bank of America boosted their target price on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the stock a "buy" rating in a report on Wednesday, June 10th. Sixteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $246.06.

Insider Transactions at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 6,000 shares of the business's stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total value of $1,143,000.00. Following the completion of the transaction, the director owned 384,682 shares in the company, valued at $73,281,921. The trade was a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the company's stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total value of $278,196.00. Following the transaction, the executive vice president directly owned 51,549 shares in the company, valued at approximately $11,950,604.67. The trade was a 2.27% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 13,098 shares of company stock valued at $2,832,086. Insiders own 4.10% of the company's stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.